Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.62 |
| ▸ | USP14 | P54578 | 10/20 | 0.58 |
| ▸ | USP7 | Q93009 | 3/20 | 0.58 |
| ▸ | USP5 | P45974 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 6/20 | 0.50 |
| ▸ | NPC1 | O15118 | 5/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23524570 | 1.00 | SMN1; SMN2 (0.62) | SMN1; SMN2USP14USP7USP5RAB9A | |
| SCHEMBL23524518 | 0.89 | SMN1; SMN2 (0.59) | SMN1; SMN2USP14USP7USP5RAB9A | |
| SCHEMBL30585406 | 0.89 | SMN1; SMN2 (0.59) | SMN1; SMN2USP14USP7USP5RAB9A | |
| SCHEMBL30585410 | 0.88 | SMN1; SMN2 (0.61) | SMN1; SMN2USP14USP7USP5RAB9A | |
| SCHEMBL23524562 | 0.88 | SMN1; SMN2 (0.61) | SMN1; SMN2USP14USP7USP5RAB9A | |
| SCHEMBL23559539 | 0.77 | SMN1; SMN2 (0.50) | SMN1; SMN2USP14USP7RAB9ANPC1 | |
| SCHEMBL23524489 | 0.77 | USP14 (0.76) | SMN1; SMN2USP14USP7USP5RAB9A | |
| SCHEMBL23524548 | 0.76 | SMN1; SMN2 (0.83) | SMN1; SMN2USP14USP7USP5RAB9A | |
| SCHEMBL23524469 | 0.75 | USP14 (0.67) | SMN1; SMN2USP14USP7USP5RAB9A | |
| SCHEMBL2028555 | 0.75 | NOTUM (0.68) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116894-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | Kineta, Inc. | 2024-04-11 | — | — | US | disclosed |
| US-11746098-B2 | Proteasome activity enhancing compounds | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746098-B2 | Proteasome activity enhancing compounds | PSMG3, PSMC1, PSMB11 | SMN1; SMN2 819/4885USP14 7/4885USP7 40/4885 |
| US-20240116894-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PSMG3, PSMC1, PSMB11 | SMN1; SMN2 819/4885USP14 7/4885USP7 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.